Betahistine or Cinnarizine for Treatment of Meniere’s Disease
Jasminka Djelilovic-Vranic, Azra Alajbegovic, Merita Tiric-Campara, Aida Volic, Zehra Sarajlic, Eldina Osmanagic, Ljubica Todorovic,Omer Beslagic
Med Arh. 2012; 66(6): 396-398
Introduction: Meniere’s disease is a condition with sudden attacks of vertigo with nausea and vomiting accompanied by loss of hearing and buzzing sensation in the ears, most commonly unilateral. The exact cause of the disease is unknown. Betahistine is the analogue of histamine with weaker agonistic effect on histamine H1 receptors and stronger effect on histamine H3 receptors, while Cinnarizine has more effective effect on H1 receptors. Goal: The aim is to determine which drug is more effective in the treatment of Meniere’s disease Betahistine or Cinnarizine. Material and methods: This study evaluates the effectiveness of Betahistine in 37 patients with the Meniere’s syndrome accompanied by classic triad of symptoms treated in hospital conditions and Cinnarizine effect in 36 patients with a less severe clinical picture, which were treated as outpatients. To all patients were conducted laboratory tests, brain CAT (to exclude possible expansive process, MS or stroke) and TCD in order to eliminate any possible circulatory disturbances in VB basin. Group with classic Meniere’s syndrome was treated at a dose of Betahistine of 3x16mg and followed 8 weeks, while the second group was treated with Cinnarizine at a dose of 2x75mg and also followed for 8 weeks. Conclusions: Already after one month of therapy was noticed better effect in case of Betahistine in terms of symptoms reduction compared to the Cinnarizine effect.
1. Celestino D, Ralli G. Incidence of Menière’s disease in Italy. Am J Otol. 1991; 12:135-138.
2. Wladislavosky-Waserman P, Facer GW, Mokri B, Kurland LT. Meniere’s disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980. Laryngoscope. 1984;94: 1098-1102.
3. Saeed S, Penney S. Diagnosis and management of Meniere’s Disease. ENT News. 2004; 13: 32-34.
4. Jonathan Hazell FRCS. London Tinnitus and Hyperacusis Centre. Information on Menier’s Syndrome, 2011.
5. Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistinee in the treatment of Ménière’s disease. Neuropsychiatr Dis Treat. 2007; 3(4): 429-440.
6. Deering RB, Prescott P, Simmons RL, Downey LJ. A double-blind crossover study comparing betahistinee and cinnarizine in the treatment of recurrent vertigo in patients in general practice. Current Medical Research and Opinion. 1986; 10: 209-214.
7. http://www.livestrong.com/article/270761-betahistinee-hydrochloride-side-effects/>>. Bergeson B. Betahistinee hydrochloride side effects.
8. Alonso-Navarro H, Jiménez-Jiménez FJ. Tardive blepharospasm associated with cinnarizine use. Clin Neuropharmacol. 2006; 29(4): 187-189.
9. Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol. 2001; 15(3): 167-272.
10. Alajbegovic A, Deljo D, Alajbegovic S, Djelilovic-Vranic J, Todorovic Lj, Tiric-Campara M. Interferon Treatment of Multiplesclerosis. Mat Soc Med. 2012; 24(1): 38-43.
11. Alajbegovic A, Todorovic Lj, Djelilovic-Vranic J, Alajbegovic S. Treatment of Patients with Multiple Sclerosis by Pulse Corticosteroid Therapy at Neurologic Clinic of Clinical Center University of Sarajevo. Mat Soc Med. 2010; 22(3): 141-144